BORTEZOMIB EFFECTIVENESS IN ONE PATIENT WITH ACQUIRED VON WILLEBRAND SYNDROME ASSOCIATED TO MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE
Résumé
Acquired von Willebrand Syndrome (AVWS) is a rare heterogeneous bleeding condition associated with several disorders, including monoclonal gammopathy of undeterminated significance (MGUS) [1-3]. Successful therapy of the underlying disorder can leads to the improvement of AVWS [1]. Regarding the association of AVWS and MGUS, no long-term successful therapy has been reported. Indeed, most of these patients are not treated on a curative goal [1]. In a few single cases anti-CD20 targeted therapy (Rituximab) has shown no efficacy [4,5]. We describe herein the case of a patient with AVWS accompanied by MGUS who was successfully treated with the proteosome inhibitor Bortezomib after failure of Rituximab.
Origine | Fichiers produits par l'(les) auteur(s) |
---|
Loading...